AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress
- Posted on March 19, 2026
- By International Business Times
- 3 Views
AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress
Shares of AIM ImmunoTech Inc. (NYSE American: AIM) rocketed higher Wednesday, closing at $1.02, up 31 cents or 43.66%, on extraordinarily heavy trading volume exceeding 183 million shares as investors reacted to a key patent milestone and ongoing clinical advancements in its lead drug Ampligen for
